Dmitry Balyasny’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,257,912
Closed -$298M 3505
2025
Q1
$298M Buy
2,257,912
+2,118,252
+1,517% +$264M 0.49% 27
2024
Q4
$11.7M Buy
+139,660
New +$11.5M 0.02% 896
2024
Q3
Sell
-406,714
Closed -$27.9M 3255
2024
Q2
$27.9M Sell
406,714
-3,920
-1% -$272K 0.05% 488
2024
Q1
$28.4M Buy
410,634
+100,641
+32% +$6.92M 0.05% 490
2023
Q4
$22.2M Buy
+309,993
New +$17.8M 0.04% 557
2023
Q3
Sell
-130,607
Closed -$8.27M 2821
2023
Q2
$8.27M Buy
130,607
+123,282
+1,683% +$7.68M 0.02% 860
2023
Q1
$397K Buy
7,325
+6,657
+997% +$322K ﹤0.01% 2016
2022
Q4
$35.4K Sell
668
-4,640
-87% -$233K ﹤0.01% 2402
2022
Q3
$247K Buy
+5,308
New +$277K ﹤0.01% 2258
2022
Q2
Sell
-31,967
Closed -$1.96M 3272
2022
Q1
$1.96M Buy
+31,967
New +$1.66M 0.01% 1379
2018
Q4
Sell
-508,750
Closed -$11M 1833
2018
Q3
$11M Buy
508,750
+50,859
+11% +$1.06M 0.05% 456
2018
Q2
$8.09M Buy
457,891
+55,765
+14% +$1.13M 0.04% 544
2018
Q1
$8.46M Buy
402,126
+291,973
+265% +$5.69M 0.04% 572
2017
Q4
$1.59M Sell
110,153
-29,200
-21% -$451K 0.01% 1207
2017
Q3
$2.2M Buy
+139,353
New +$2.04M 0.01% 929
2016
Q2
Sell
-55,100
Closed -$1.53M 1500
2016
Q1
$1.53M Buy
55,100
+45,730
+488% +$1.52M 0.01% 731
2015
Q4
$504K Buy
+9,370
New +$473K ﹤0.01% 828
2015
Q3
Sell
-50,000
Closed -$1.63M 1431
2015
Q2
$1.6M Buy
+50,000
New +$1.27M 0.01% 762

Other funds holding ITCI

Dmitry Balyasny's ITCI Position: Q2 2025 in Review

Dmitry Balyasny sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,257,912 shares — an estimated $298M sold.

Dmitry Balyasny first reported a position in ITCI in Q2 2015 and held it in 18 quarters. The position peaked at $298M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Dmitry Balyasny reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 2,257,912 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $298M.
  • Dmitry Balyasny first reported a position in Intra-Cellular Therapies Inc. in Q2 2015 and held it in 18 quarters.
  • Dmitry Balyasny's Intra-Cellular Therapies Inc. position peaked at $298M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.